Advances in Rejection Management: Prevention and Treatment

Claire R. Harrington, Guang Yu Yang, Josh Levitsky*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Extended survival of liver transplant recipients has brought rejection management to the forefront of liver transplant research. This article discusses T-cell–mediated rejection, antibody-mediated rejection, and chronic rejection. We focus on the prevention and then discuss treatment options. Future directions of rejection management include biomarkers of rejection, which may allow for monitoring of patients who are considered high risk for rejection and detection of rejection before there is any clinical evidence to improve graft and patient survival. With improved graft life and survival of liver transplant recipients, the new frontier of rejection management focuses on immunosuppression minimization, withdrawal, and personalization.

Original languageEnglish (US)
JournalClinics in liver disease
DOIs
StateAccepted/In press - 2020

Keywords

  • Antibody-mediated rejection
  • Biomarkers of rejection
  • Immunosuppression minimization
  • T-cell mediated rejection
  • Tolerance

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Advances in Rejection Management: Prevention and Treatment'. Together they form a unique fingerprint.

Cite this